Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ranibizumab in idiopathic macular telangiectasia type 2
2006-006233-40Phase 2Completed
- Sponsor
- University Eye Hospital Bonn
- Start
- Mar 2007
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ranibizumab in idiopathic macular telangiectasia (MacTel) and macular telangiectasia (MacTel), sponsored by University Eye Hospital Bonn. Primary endpoint: Change in best corrected visual acuity at 12 months. Started Mar 2007; status: completed.
02
Drugs
ranibizumab
03
Conditions
idiopathic macular telangiectasia (MacTel)macular telangiectasia (MacTel)
Beyond the preview
Go deeper on 2006-006233-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-006233-40.